Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC)

Background: FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve pts. with MPC, but carries an unfavorable adverse event (AE) profile.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Jg. 16; H. 4; S. S30 - S31
Hauptverfasser: Ozaka, Masato, Ishii, Hiroshi, Sato, Tosiya, Ueno, Makoto, Ikeda, Masafumi, Uesugi, Kazuhiro, Sata, Naohiro, Miyashita, Kouichirou, Mizuno, Nobumasa, Tsuji, Kunihiro, Okusaka, Takuji, Furuse, Junji
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Philadelphia Elsevier B.V 01.08.2016
Elsevier Limited
Schlagworte:
Chemotherapy
Confidence intervals
Endocrinology & Metabolism
Gastroenterology and Hepatology
Metastasis
Neutropenia
Pancreatic cancer
ISSN:1424-3903, 1424-3911
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Background: FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve pts. with MPC, but carries an unfavorable adverse event (AE) profile.
AbstractList Background: FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve pts. with MPC, but carries an unfavorable adverse event (AE) profile.
Author Ozaka, Masato
Sato, Tosiya
Ueno, Makoto
Furuse, Junji
Tsuji, Kunihiro
Ishii, Hiroshi
Ikeda, Masafumi
Sata, Naohiro
Miyashita, Kouichirou
Uesugi, Kazuhiro
Okusaka, Takuji
Mizuno, Nobumasa
Author_xml – sequence: 1
  givenname: Masato
  surname: Ozaka
  fullname: Ozaka, Masato
  organization: The Cancer Institute Hospital of JFCR, Japan
– sequence: 2
  givenname: Hiroshi
  surname: Ishii
  fullname: Ishii, Hiroshi
  organization: National Hospital Organization Shikoku Cancer Center, Japan
– sequence: 3
  givenname: Tosiya
  surname: Sato
  fullname: Sato, Tosiya
  organization: Kyoto University School of Public Health, Japan
– sequence: 4
  givenname: Makoto
  surname: Ueno
  fullname: Ueno, Makoto
  organization: Kanagawa Cancer Center, Japan
– sequence: 5
  givenname: Masafumi
  surname: Ikeda
  fullname: Ikeda, Masafumi
  organization: National Cancer Center Hospital East, Japan
– sequence: 6
  givenname: Kazuhiro
  surname: Uesugi
  fullname: Uesugi, Kazuhiro
  organization: National Hospital Organization Shikoku Cancer Center, Japan
– sequence: 7
  givenname: Naohiro
  surname: Sata
  fullname: Sata, Naohiro
  organization: Jichi Medical University School of Medicine, Japan
– sequence: 8
  givenname: Kouichirou
  surname: Miyashita
  fullname: Miyashita, Kouichirou
  organization: Showa University Northern Yokohama Hospital, Japan
– sequence: 9
  givenname: Nobumasa
  surname: Mizuno
  fullname: Mizuno, Nobumasa
  organization: Aichi Cancer Center Hospital, Japan
– sequence: 10
  givenname: Kunihiro
  surname: Tsuji
  fullname: Tsuji, Kunihiro
  organization: Ishikawa Prefectural Central Hospital, Japan
– sequence: 11
  givenname: Takuji
  surname: Okusaka
  fullname: Okusaka, Takuji
  organization: National Cancer Center Hospital, Japan
– sequence: 12
  givenname: Junji
  surname: Furuse
  fullname: Furuse, Junji
  organization: Kyorin University School of Medicine, Japan
BookMark eNqFUV2L1DAUDbKCu6M_wLeAL-tDa27api2CIIPjFkZn8QN8C2l6w2Rs09mkszK_yh-xf8zUEYUF9SX3kHvOyb05F-TMjQ4JeQosBQbixS7dK5fyCFMmUuDsATmHnOdJVgOc_cYse0QuQtgxxjlAfU7c9VYFpE1Dw3TojnQ0dBg7ayx2dLVZr5oPzfvNF2pGT_UWh3Haolf7Y-LU3fdbpHs1WXRToN_stKUDTipM8UrHhtMef0IdIXp6-e56-fwxeWhUH_DJr7ogn1dvPi2vkvXmbbN8vU40F6xMdKVbjXnLqpwxLIpatxnkmanaioMpcwOl6YwSJYJRIAzLVC00VgpUC7rm2YJcnnz3frw5YJjkYIPGvlcOx0OQULFKAC-LMlKf3aPuxoN3cbqZVRRZzeOxIHBiaT-G4NHIvbeD8kcJTM4JyJ2MO8s5AcmEjAlEzcuTBuOmtxa9DDr-lsbOetST7Eb7T_Wre2rdW2e16r_iEcOfIWXgksmPc8JzwCAyVtSFiAb13w3-8_gPh463vg
ContentType Journal Article
Copyright 2016
Copyright Elsevier Limited Aug/Sep 2016
Copyright_xml – notice: 2016
– notice: Copyright Elsevier Limited Aug/Sep 2016
DBID AAYXX
CITATION
7T5
H94
K9.
NAPCQ
DOI 10.1016/j.pan.2016.06.120
DatabaseName CrossRef
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
DatabaseTitle CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
DatabaseTitleList AIDS and Cancer Research Abstracts
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1424-3911
EndPage S31
ExternalDocumentID 4122467881
10_1016_j_pan_2016_06_120
S1424390316305956
1_s2_0_S1424390316305956
GroupedDBID ---
--K
-RU
.1-
.FO
0R~
0~B
123
1P~
29O
36B
4.4
457
53G
8UI
AAEDT
AAEDW
AAIKJ
AAJMK
AAKOC
AALRI
AAQFI
AAQXK
AATTM
AAXKI
AAXUO
AAYIC
AAYWO
ABBTS
ABJNI
ABLJU
ABMAC
ABWCG
ABWVN
ACDAQ
ACGFO
ACGFS
ACIEU
ACLOT
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
AEBSH
AEIPS
AENEX
AEUPX
AEVXI
AEYAO
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGHFR
AGQPQ
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BELOY
BKEYQ
BKOJK
BNPGV
BPHCQ
BVXVI
CAG
COF
CS3
CYUIP
DU5
E0A
EBS
EFJIC
EFKBS
EFLBG
EJD
EMB
EMOBN
FB.
FDB
FEDTE
FGOYB
FYGXN
GBLVA
HVGLF
HZ~
KOM
KUZGX
M41
N9A
O1H
O9-
OC.
ON0
P2P
PQQKQ
PROAC
R2-
ROL
SEL
SPCBC
SSH
SSZ
SV3
T5K
UJ6
WOW
Z5R
3V.
7RV
AACTN
ADPAM
AFCTW
AFKWA
BENPR
RIG
RKO
AAIAV
ABLVK
AGZHU
ALXNB
AZPMC
AAYXX
CITATION
7T5
H94
K9.
NAPCQ
ID FETCH-LOGICAL-c2607-c8cbce4b08400e559cb3143f8b821f74f17fdfa67e1fa16f03a96ce8a1ab1c923
ISSN 1424-3903
IngestDate Thu Oct 02 10:32:40 EDT 2025
Fri Oct 03 04:01:16 EDT 2025
Sat Nov 29 05:47:50 EST 2025
Fri Feb 23 02:19:43 EST 2024
Sun Feb 23 10:19:50 EST 2025
Tue Oct 14 19:30:35 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2607-c8cbce4b08400e559cb3143f8b821f74f17fdfa67e1fa16f03a96ce8a1ab1c923
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PQID 1805539255
PQPubID 25450
ParticipantIDs proquest_miscellaneous_1808612757
proquest_journals_1805539255
crossref_primary_10_1016_j_pan_2016_06_120
elsevier_sciencedirect_doi_10_1016_j_pan_2016_06_120
elsevier_clinicalkeyesjournals_1_s2_0_S1424390316305956
elsevier_clinicalkey_doi_10_1016_j_pan_2016_06_120
PublicationCentury 2000
PublicationDate 20160801
PublicationDateYYYYMMDD 2016-08-01
PublicationDate_xml – month: 08
  year: 2016
  text: 20160801
  day: 01
PublicationDecade 2010
PublicationPlace Philadelphia
PublicationPlace_xml – name: Philadelphia
PublicationTitle Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
PublicationYear 2016
Publisher Elsevier B.V
Elsevier Limited
Publisher_xml – name: Elsevier B.V
– name: Elsevier Limited
SSID ssj0022119
Score 2.091916
Snippet Background: FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve pts. with MPC, but carries an unfavorable adverse event...
SourceID proquest
crossref
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage S30
SubjectTerms Chemotherapy
Confidence intervals
Endocrinology & Metabolism
Gastroenterology and Hepatology
Metastasis
Neutropenia
Pancreatic cancer
Title Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC)
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1424390316305956
https://www.clinicalkey.es/playcontent/1-s2.0-S1424390316305956
https://dx.doi.org/10.1016/j.pan.2016.06.120
https://www.proquest.com/docview/1805539255
https://www.proquest.com/docview/1808612757
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: ScienceDirect database
  customDbUrl:
  eissn: 1424-3911
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022119
  issn: 1424-3903
  databaseCode: AIEXJ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbKxgMvCBiIjoGMBBNQpYpz72OZVhFU2oq1Ut8sx7O1bDQZ6zat_F_-B8eOnWxjg_HAS9QmvkQ-X3wuPheE3vQId6X0fWffF8wJIoAxAzI7ip_48IGJKMt0sYl4NErm896k1fppY2HOv8VFkVxc9I7_K6nhHhBbhc7-A7nrQeEG_AaiwxXIDtc7EX5yAIypk6ZV5lh9fl7u51KJmoPxcJB-TUfjufYuBHotTADWyimY8iEyaVZNzNtCnDIVcZRzeFBU8iVXfmJcJaDwki-THWtJMPLtxDSrMjvdlqOi8di0pshLKNFeeVeHASG4P1H2i26323kbftR26q6tja5MxD_YEatCj5bQq8H7QV5V5c5BGDjIa3MS08WjOtNyma9qvjQTugw5jHFUmjGMOYREtTOe3cEDL3D8nutf2eKjS1AOLu3Xe-ZQSJh_5EauUhk4Druw1MoZMFIZX4nnNizUug2MxnQwGw7pdHc-3T7-7qjiZsoJwFR6uYfWvTjswea73k93559ry4BKs6fD4My72-N37Yh4bdbbBKhrooSWj6aP0EOj2OB-BcjHqCWKJ2ijDxQuFyu8jbWrsabnBlpojOI0xRqjuJTYYhQ3GMWAUfw7RrHFKFYYxQ1GcYNRXGEUvwOEvn-KZoPd6c4nx9T9cDho17HDE55xEWRuAgxGgMrLMx_EeplkiUdkHEgSy33JolgQyUgkXZ_1Ii4SRlhGOGgsz9BaURbiOcLEi2QsY5BCQfAXUvkEZMDjSSilcDlhbfTBLiY9rtK7UOv3eEjhtalaeepGFFa-jTy73NTGLQOnpQCTP3WKb-okluarW1JClx516Z6iviI-aEig84RRGwV1TyMOV2Lu3ybcskigzRyJG4agCoVhG72uHwMnUceDrBDlmW6TRKreQ7x5hzYv0IPm89tCa6cnZ-Ilus_PT_PlySsD8F9_3OqO
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+II+study+of+modified+FOLFIRINOX+for+chemotherapy-naive+patients+with+metastatic+pancreatic+cancer+%28MPC%29&rft.jtitle=Pancreatology+%3A+official+journal+of+the+International+Association+of+Pancreatology+%28IAP%29+...+%5Bet+al.%5D&rft.au=Ozaka%2C+Masato&rft.au=Ishii%2C+Hiroshi&rft.au=Sato%2C+Tosiya&rft.au=Ueno%2C+Makoto&rft.date=2016-08-01&rft.issn=1424-3903&rft.volume=16&rft.issue=4&rft.spage=S30&rft.epage=S31&rft_id=info:doi/10.1016%2Fj.pan.2016.06.120&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14243903%2FS1424390316X00087%2Fcov150h.gif